Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, diagnostic test maker Meridian Bioscience (NAS: VIVO) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Meridian Bioscience's business and see what CAPS investors are saying about the stock right now.
Meridian Bioscience facts
CEO John Kraeutler (since 2008)
Return on Equity (Average, Past 3 Years)
$27.9 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 478 members who have rated Meridian Bioscience believe the stock will outperform the S&P 500 going forward.
[Meridian Bioscience] makes a range of diagnostic tests for foodborne, parasitic, viral, and other diseases that you can do at home. ...
With increasing threats to the food supply and environmental concerns such as lack of proper water for both humans and livestock, these tests will be both helpful and in greater demand in coming years.
Add to that its great balance sheet -- currently with zero debt and current ratio of over 5, plus high insider ownership, generous dividend, and 5-year projected growth in the mid-teens, and we have an excellent addition to anyone's health-oriented portfolio.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Meridian Bioscience may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.
The article 5-Star Stocks Poised to Pop: Meridian Bioscience originally appeared on Fool.com.
Fool contributorBrian Pacamparaowns no position in any of the companies mentioned. The Motley Fool owns shares of Abbott.Motley Fool newsletter serviceshave recommended buying shares of Becton. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Fool'sdisclosure policyalways gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.